ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
ImmunoPrecise Antibodies Ltd. (IPA)
Company Research
Source: Business Wire
Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, British Columbia & ZHUHAI, China--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, and Biotheus Inc. (Biotheus), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, jointly announce that the two parties have entered into a Material Transfer and Evaluation Agreement (MTEA) pertaining to a Talem therapeutic antibody asset for the development of a bispecific therapy against solid tumors. Under this MTEA, Biotheus will obtain the rights to further evaluate the suitability of Talem’s Artificial Intelligence (AI)-enhanced TATX-20 lead candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors.This press release features multimedia. View the full release here: https
Show less
Read more
Impact Snapshot
Event Time:
IPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPA alerts
High impacting ImmunoPrecise Antibodies Ltd. news events
Weekly update
A roundup of the hottest topics
IPA
News
- $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesBusiness Wire
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation [Yahoo! Finance]Yahoo! Finance
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationBusiness Wire
- ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI TechnologyBusiness Wire
- ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024Business Wire
IPA
Earnings
- 9/16/24 - Miss
IPA
Analyst Actions
- 9/17/24 - HC Wainwright
IPA
Sec Filings
- 11/18/24 - Form 6-K
- 11/13/24 - Form 6-K
- 11/4/24 - Form 6-K
- IPA's page on the SEC website